文献速递肝病消化道肿瘤与早癌

肝病中的自噬:转化时机已到?

Autophagy in liver diseases: Time for translation?
PubMed 文献 · J Hepatol · 2019-01-31

自噬是通过清除错误折叠蛋白、受损细胞器和脂滴来维持肝脏稳态的分解代谢通路,其失调与多种肝病相关。增强自噬可能预防α1-抗胰蛋白酶缺乏症、Wilson病、急性肝损伤、非酒精性脂肪性肝炎和慢性酒精相关肝病等进展,但在纤维化、肝细胞癌等情况下需考虑细胞类型和最佳治疗时间窗。识别自噬生物标志物和体内监测自噬流的方法对个性化自噬靶向策略的发展至关重要。

要点

  • 自噬失调与多种肝病相关,调节自噬被视为潜在新治疗策略。
  • 增强自噬可能预防储积病、急性肝损伤、非酒精性脂肪性肝炎和慢性酒精相关肝病进展。
  • 在纤维化和肝细胞癌等情况下,自噬作用因细胞类型和疾病阶段而异,需考虑靶向特定细胞和最佳时间窗。

核心结论

  • 自噬调节是肝病潜在治疗策略,但需考虑细胞类型特异性、最佳治疗时间窗,并开发自噬生物标志物和体内监测自噬流的方法以推动个性化策略。

研究设计与样本

  • 综述,检索范围未明确报告。

主要发现

  • 自噬通过清除错误折叠蛋白、受损细胞器和脂滴参与能量平衡和细胞质质量控制,维持肝脏稳态。
  • 自噬不仅调节肝细胞功能,还影响内皮细胞、巨噬细胞和肝星状细胞等非实质细胞。
  • 自噬失调与多种肝病相关,增强自噬可能预防α1-抗胰蛋白酶缺乏症、Wilson病、急性肝损伤、非酒精性脂肪性肝炎和慢性酒精相关肝病进展。
  • 在纤维化中靶向特定肝细胞需考虑,因自噬作用取决于细胞类型;自噬在疾病初期可能有益,在晚期如肝细胞癌可能有害。

关键数值与推荐

  • 增强自噬可能预防储积病(α1-抗胰蛋白酶缺乏症、Wilson病)、急性肝损伤、非酒精性脂肪性肝炎和慢性酒精相关肝病进展。
  • 在纤维化中,靶向特定肝细胞必须被考虑,因自噬根据细胞类型显示相反功能。
  • 应确定最佳治疗时间窗,因自噬在疾病初期可能有益,在晚期如肝细胞癌可能有害。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Autophagy is a self-eating catabolic pathway that contributes to liver homeostasis through its role in energy balance and in the quality control of the cytoplasm, by removing misfolded proteins, damaged organelles and lipid droplets. Autophagy not only regulates hepatocyte functions but also impacts on non-parenchymal cells, such as endothelial cells, macrophages and hepatic stellate cells. Deregulation of autophagy has been linked to many liver diseases and its modulation is now recognized as a potential new therapeutic strategy. Indeed, enhancing autophagy may prevent the progression of a number of liver diseases, including storage disorders (alpha-1 antitrypsin deficiency, Wilson's disease), acute liver injury, non-alcoholic steatohepatitis and chronic alcohol-related liver disease. Nevertheless, in some situations such as fibrosis, targeting specific liver cells must be considered, as autophagy displays opposing functions depending on the cell type. In addition, an optimal therapeutic time-window should be identified, since autophagy might be beneficial in the initial stages of disease, but detrimental at more advanced stages, as in the case of hepatocellular carcinoma. Finally, identifying biomarkers of autophagy and methods to monitor autophagic flux in vivo are important steps for the future development of personalized autophagy-targeting strategies. In this review, we provide an update on the regulatory role of autophagy in various aspects of liver pathophysiology, describing the different strategies to manipulate autophagy and discussing the potential to modulate autophagy as a therapeutic strategy in the context of liver diseases.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Allaire M, Rautou PE, Codogno P, et al. Autophagy in liver diseases: Time for translation? J Hepatol. 2019. PMID: 30711404. doi:10.1016/j.jhep.2019.01.026

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。